The short answer
Oral estrogen raises the risk of blood clots. Large observational studies found transdermal estradiol at standard doses was not associated with the same increase, and micronized progesterone appears more neutral than some synthetic progestins. FDA labels still list a history of clots as a contraindication, so after a clot, non-hormonal options are often first, and any hormone therapy is an individual specialist decision.
No advertising or analytics trackers run on Specialized Care pages. Reading them is never linked to your identity. Our privacy pledge
Why the route of estrogen matters
Estrogen taken by mouth passes through the liver first, where it increases clotting factors. Estradiol through the skin bypasses that first pass. In a large UK study of over 80,000 cases, oral hormone therapy was linked with higher clot risk, while transdermal estradiol was not associated with a significant increase. These are observational findings, not randomized trial results.
Situations this pathway covers
- Past deep vein thrombosis (DVT) or pulmonary embolism (PE)
- Inherited clotting conditions such as factor V Leiden
- Antiphospholipid syndrome
- Strong family history of clots
- Currently taking an anticoagulant
Treatment options
| Option | Clot considerations |
|---|---|
| Non-hormonal medicines (fezolinetant, elinzanetant, SNRIs, gabapentin) | No estrogen-related clot risk; each has its own safety checks |
| Vaginal estrogen, low dose | Minimal absorption; often considered for genitourinary symptoms |
| Transdermal estradiol with micronized progesterone | May be considered individually with specialist input; FDA labels list prior clots as a contraindication |
| Oral estrogen | Generally avoided after a clot |
If you take a blood thinner
Some people on long-term anticoagulation are offered transdermal hormone therapy after discussion with their hematologist. Heavy or unexpected bleeding should be reported. Never stop an anticoagulant without your prescriber.
Warning signs
Seek urgent care for leg swelling or pain in one leg, sudden breathlessness, chest pain, or coughing blood. Call 911 for chest pain or severe breathlessness.
Specialized care pathway
Care that takes your history into account
A private preparation tool builds a summary for a licensed Kindr clinician. Your answers stay in your browser and are not saved or sent.
Questions, answered
Common questions
Can I take HRT if I have had a blood clot?
+
Oral estrogen is generally avoided. Transdermal estradiol may be considered in selected cases with specialist input, though labels list prior clots as a contraindication. Non-hormonal options are often tried first.
Does the estrogen patch cause blood clots?
+
Large observational studies found transdermal estradiol at standard doses was not associated with the increased clot risk seen with oral estrogen. It is not randomized trial evidence, and individual risk matters.
Is vaginal estrogen safe with a clot history?
+
Low-dose vaginal estrogen has minimal absorption and is often considered for vaginal and urinary symptoms. Your clinician weighs your specific history.
What non-hormonal options help hot flashes?
+
Fezolinetant and elinzanetant, SNRIs such as venlafaxine, SSRIs, gabapentin and oxybutynin. None carry an estrogen-related clot risk, but each has its own side effects and checks.
WRITTEN & MEDICALLY REVIEWED BY
Kindr Health Clinical Team
Kindr Health Inc. — Editorial & Clinical Team, led by Kevin Wolfe, CMO
Kindr’s clinical content is written and reviewed by board-certified clinicians who prescribe hormone therapy every day across all 50 states — menopause-focused physicians, nurse practitioners, and pharmacists working under Kindr Health, Inc.’s organizational clinical oversight. Every page is checked against current NAMS and ACOG guidance, FDA labeling, and the primary literature before publication, then re-reviewed on a rolling schedule when guidance changes.
Organizational NPI 1609792902 · Last reviewed October 5, 2026 · Editorial policy
Educational content only — not a substitute for individual medical advice, diagnosis, or treatment.
SOURCES & REFERENCES
Every clinical claim on this page is sourced.
- Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies (Vinogradova Y, et al.) (2019) — BMJ. doi.org/10.1136/bmj.k4810
- The 2022 Hormone Therapy Position Statement of The North American Menopause Society (2022) — The Menopause Society. www.menopause.org/docs/default-source/professional/nams-2022-hormone-therapy-position-statement.pdf
- The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society (2023) — Menopause (journal of The Menopause Society). pubmed.ncbi.nlm.nih.gov/?term=2023+nonhormone+therapy+position+statement+North+American+Menopause+Society
- American Society of Hematology 2020 guidelines for management of venous thromboembolism (2020) — Blood Advances. doi.org/10.1182/bloodadvances.2020001830